Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Everyman Media Group (EMAN) by Steve Moore in ShareProphets
- Hold BP (BP.) by Tom Winnifrith in ShareProphets
- Hold BP (BP.) by Steve Moore in ShareProphets
- Buy Fresnillo (FRES) by Citi
- Buy RM (RM.) by Steve Moore in ShareProphets
- Buy Capital Limited (DI) (CAPD) by Steve Moore in ShareProphets
- Hold JD Sports Fashion (JD.) by Mark Hartley in The Motley Fool
- Speculative Buy Kodal Minerals (KOD) by Canaccord Genuity
- Buy Renew Holdings (RNWH) by Peel Hunt
- Sell Crimson Tide (TIDE) by Steve Moore in ShareProphets
- Hold Glencore (GLEN) by Harvey Jones in The Motley Fool
- Hold Burberry Group (BRBY) by Harvey Jones in The Motley Fool
- Add Aviva (AV.) by Andrew Mackie in The Motley Fool
- Hold Lloyds Banking Group (LLOY) by Dr. James Fox in The Motley Fool
- Hold BP (BP.) by Harvey Jones in The Motley Fool
- Hold Lloyds Banking Group (LLOY) by Alan Oscroft in The Motley Fool
- Sell Aptamer Group (APTA) by Steve Moore in ShareProphets
- Sell Windar Photonics (WPHO) by Steve Moore in ShareProphets
- Avoid URU Metals Ltd. (DI) (URU) by Nigel Somerville in ShareProphets
- Sell Videndum (VID) by Steve Moore in ShareProphets
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 61 open tips for Shield Therapeutics (STX)
| Latest Bid : 9.70p | Latest Ask : 10.30p |
| High Today : 10.35p | Low Today : 9.50p |
| This Years High : 11.80p | This Years Low : 2.25p |
| Volume : 2,635,198 | MKT Cap : £78.2M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 45.99% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | 21.95% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -244.83% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 30.72% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 40.85% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 9.70p | Latest Ask : 10.30p |
| High Today : 10.35p | Low Today : 9.50p |
| This Years High : 11.80p | This Years Low : 2.25p |
| Volume : 2,635,198 | MKT Cap : £78.2M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Peel Hunt | Premium Only | 2025-11-07 16:31:00 07/11/2025 | 45.99% |
| Buy | Peel Hunt | Premium Only | 2025-09-15 11:19:00 15/09/2025 | 21.95% |
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | -244.83% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | 30.72% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | 40.85% |